RMRomina Monzani

Romina Monzani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Romina Monzani has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Eleonora Ferrari

    Affiliations European Institute for Research in Cystic Fibrosis, San Raffaele Scientific Institute, Milan, Italy, Dipartimento di Scienze della Salute, University of Eastern Piedmont, Novara, Italy

    6 shared publications
  • Guido Kroemer

    Sorbonne Universite

    5 shared publications
  • Speranza Esposito

    European Institute for Research in Cystic Fibrosis, San Raffaele Scientific Institute, Milan 20132, Italy

    5 shared publications
  • Antonella Tosco

    Centro di Riferimento Regionale per La Cura della Fibrosi Cistica Pediatrico, Dipartimento Materno-Infantile, Azienda Ospedaliera Universitaria Federico II, 80131 Naples, Italy

    4 shared publications
  • Federica Rossin

    Department of Biology University of Rome "Tor Vergata", Rome 00133, Italy

    4 shared publications
  • Valeria Raia

    Affiliation Dipartimento di Scienze Mediche Traslazionali, University of Naples Federico II, Naples, Italy

    4 shared publications

Latest Publications

  • Open Access

    Impaired cholesterol metabolism in the mouse model of cystic fibrosis. A preliminary study

    by Felice Amato, Alice Castaldo, Giuseppe Castaldo, Gustavo Cernera, Gaetano Corso, Eleonora Ferrari, Monica Gelzo, Romina Monzani, Valeria Rachela Villella, Valeria Raia

    This study aims to investigate cholesterol metabolism in a mouse model with cystic fibrosis (CF) by the comparison of affected homozygous versuswild type(WT) mice. In particular, we evaluated the effects of a diet enriched with cholesterol in both mice groups in comparison with the normal diet. To this purpose, beyond serum and liver cholesterol, we analyzed serum phytosterols as indirect markers of intestinal absorption of cholesterol, liver lathosterol as indirect marker ofde novocholesterol synthesis, liver cholestanol (a catabolite of bile salts synthesis) and the liver mRNA levels ofLDL receptor(LDLR),3-hydroxy-3-methylglutaryl-CoA reductase(HMG-CoAR),acyl CoA:cholesterol acyl transferase 2(ACAT2),cytochrome P450 7A1(CYP7A1) andtumor necrosis factor alpha(TNFα). CF mice showed lower intestinal absorption and higher liver synthesis of cholesterol than WT mice. In WT mice, the cholesterol supplementation inhibits the synthesis of liver cholesterol and enhances its catabolism, while in CF mice we did not observe a reduction ofLDLRandHMG-CoARexpression (probably due to an altered feed-back), causing an increase of intracellular cholesterol. In addition, we observed a further increase (5-fold) inTNFαmRNA levels. This preliminary study suggests that in CF mice there is a vicious circle in which the altered synthesis/secretion of bile salts may reduce the digestion/absorption of cholesterol. As a result, the liver increases the biosynthesis of cholesterol that accumulates in the cells, triggering inflammation and further compromising the metabolism of bile salts.


  • Ferroptosis: a new unexpected chance to treat metastatic melanoma?

    by Mara Gagliardi, Valentina Saverio, Romina Monzani, Eleonora Ferrari, Mauro Piacentini, Marco Corazzari

    Human skin melanoma is one of the most aggressive and difficult to treat human malignancies, with an increasing incidence over the years. While the resection of the early diagnosed primary tumor remains the best clinical approach, advanced/metastatic melanoma still remains with a poor prognosis. Indeed, although enormous progress in the therapeutic treatment of human tumors has been made in recent years, patients affected by metastatic melanoma are still poorly affected by these clinical advances. Therefore, new valuable therapeutic approaches are urgently needed, to design and define effective treatments to consistently increase the overall survival rate of patients affected by this malignancy. In this review we summarize the main signaling pathways studied to kill human skin melanoma, and introduce the ferroptotic cell death as a new pathway to be explored to eradicate this tumor.


  • Genistein antagonizes gliadin-induced CFTR malfunction in models of celiac disease

    by Speranza Esposito, Valeria Rachela Villella, Eleonora Ferrari, Romina Monzani, Antonella Tosco, Federica Rossin, Manuela D’eLetto, Alice Castaldo, Alessandro Luciani, Marco Silano, et al.

    In celiac disease (CD), an intolerance to dietary gluten/gliadin, antigenic gliadin peptides trigger an HLA-DQ2/DQ8-restricted adaptive Th1 immune response. Epithelial stress, induced by other non-antigenic gliadin peptides, is required for gliadin to become fully immunogenic. We found that cystic-fibrosis-transmembrane-conductance-regulator (CFTR) acts as membrane receptor for gliadin-derived peptide P31-43, as it binds to CFTR and impairs its channel function. P31-43-induced CFTR malfunction generates epithelial stress and intestinal inflammation. Maintaining CFTR in an active open conformation by the CFTR potentiators VX-770 (Ivacaftor) or Vrx-532, prevents P31-43 binding to CFTR and controls gliadin-induced manifestations. Here, we evaluated the possibility that the over-the-counter nutraceutical genistein, known to potentiate CFTR function, would allow to control gliadin-induced alterations. We demonstrated that pre-treatment with genistein prevented P31-43-induced CFTR malfunction and an epithelial stress response in Caco-2 cells. These effects were abrogated when the CFTR gene was knocked out by CRISP/Cas9 technology, indicating that genistein protects intestinal epithelial cells by potentiating CFTR function. Notably, genistein protected gliadin-sensitive mice from intestinal CFTR malfunction and gliadin-induced inflammation as it prevented gliadin-induced IFN-γ production by celiac peripheral-blood-mononuclear-cells (PBMC) cultured ex-vivo in the presence of P31-43-challenged Caco-2 cells. Our results indicate that natural compounds capable to increase CFTR channel gating might be used for the treatment of CD.


  • Open Access

    Autophagy suppresses the pathogenic immune response to dietary antigens in cystic fibrosis

    by Valeria R. Villella, Speranza Esposito, Eleonora Ferrari, Romina Monzani, Antonella Tosco, Federica Rossin, Alice Castaldo, Marco Silano, Gian Luigi Marseglia, Luigina Romani, et al.

    Under physiological conditions, a finely tuned system of cellular adaptation allows the intestinal mucosa to maintain the gut barrier function while avoiding excessive immune responses to non-self-antigens from dietary origin or from commensal microbes. This homeostatic function is compromised in cystic fibrosis (CF) due to loss-of-function mutations in the CF transmembrane conductance regulator (CFTR). Recently, we reported that mice bearing defective CFTR are abnormally susceptible to a celiac disease-like enteropathy, in thus far that oral challenge with the gluten derivative gliadin elicits an inflammatory response. However, the mechanisms through which CFTR malfunction drives such an exaggerated response to dietary protein remains elusive. Here we demonstrate that the proteostasis regulator/transglutaminase 2 (TGM2) inhibitor cysteamine restores reduced Beclin 1 (BECN1) protein levels in mice bearing cysteamine-rescuable F508del-CFTR mutant, either in homozygosis or in compound heterozygosis with a null allele, but not in knock-out CFTR mice. When cysteamine restored BECN1 expression, autophagy was increased and gliadin-induced inflammation was reduced. The beneficial effects of cysteamine on F508del-CFTR mice were lost when these mice were backcrossed into a Becn1 haploinsufficient/autophagy-deficient background. Conversely, the transfection-enforced expression of BECN1 in human intestinal epithelial Caco-2 cells mitigated the pro-inflammatory cellular stress response elicited by the gliadin-derived P31–43 peptide. In conclusion, our data provide the proof-of-concept that autophagy stimulation may mitigate the intestinal malfunction of CF patients.


  • Open Access

    A pathogenic role for cystic fibrosis transmembrane conductance regulator in celiac disease

    by Valeria R Villella, Andrea Venerando, Giorgio Cozza, Speranza Esposito, Eleonora Ferrari, Romina Monzani, Mara C Spinella, Vasilis Oikonomou, Giorgia Renga, Antonella Tosco, et al.

    EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.


  • Open Access

    TG2 regulates the heat‐shock response by the post‐translational modification of HSF1

    by Federica Rossin, Valeria Rachela Villella, Manuela D'ELetto, Maria Grazia Farrace, Speranza Esposito, Eleonora Ferrari, Romina Monzani, Luca Occhigrossi, Vittoria Pagliarini, Claudio Sette, et al.

    Heat‐shock factor 1 (HSF1) is the master transcription factor that regulates the response to proteotoxic stress by controlling the transcription of many stress‐responsive genes including the heat‐shock proteins. Here, we show a novel molecular mechanism controlling the activation of HSF1. We demonstrate that transglutaminase type 2 (TG2), dependent on its protein disulphide isomerase activity, triggers the trimerization and activation of HSF1 regulating adaptation to stress and proteostasis impairment. In particular, we find that TG2 loss of function correlates with a defect in the nuclear translocation of HSF1 and in its DNA‐binding ability to the HSP70 promoter. We show that the inhibition of TG2 restores the unbalance in HSF1‐HSP70 pathway in cystic fibrosis (CF), a human disorder characterized by deregulation of proteostasis. The absence of TG2 leads to an increase of about 40% in CFTR function in a new experimental CF mouse model lacking TG2. Altogether, these results indicate that TG2 plays a key role in the regulation of cellular proteostasis under stressful cellular conditions through the modulation of the heat‐shock response.


  • Open Access

    Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation

    by Eleonora Ferrari, Romina Monzani, Valeria R Villella, Speranza Esposito, Francesca Saluzzo, Federica Rossin, Manuela D'ELetto, Antonella Tosco, Fabiola De Gregorio, Valentina Izzo, et al.

    Cystic fibrosis (CF), the most common lethal monogenic disease in Caucasians, is characterized by recurrent bacterial infections and colonization, mainly by Pseudomonas aeruginosa, resulting in unresolved airway inflammation. CF is caused by mutations in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which functions as a chloride channel in epithelial cells, macrophages, and other cell types. Impaired bacterial handling by macrophages is a feature of CF airways, although it is still debated how defective CFTR impairs bacterial killing. Recent evidence indicates that a defective autophagy in CF macrophages leads to alterations of bacterial clearance upon infection. Here we use bone marrow-derived macrophages from transgenic mice to provide the genetic proof that defective CFTR compromises both uptake and clearance of internalized Pseudomonas aeruginosa. We demonstrate that the proteostasis regulator cysteamine, which rescues the function of the most common F508del-CFTR mutant and hence reduces lung inflammation in CF patients, can also repair the defects of CF macrophages, thus restoring both bacterial internalization and clearance through a process that involves upregulation of the pro-autophagic protein Beclin 1 and re-establishment of the autophagic pathway. Altogether these results indicate that cysteamine restores the function of several distinct cell types, including that of macrophages, which might contribute to its beneficial effects on CF.